Olanzapine/Fluoxetine Combination Affirmed for Bipolar DepressionJuly 17th 2013
A recent meta-analysis supports evidence of the effectiveness of the fixed olanzapine/fluoxetine combination (Symbyax) in treating the depressive phase of bipolar disorder. Response was ranked higher, but with no more adverse effects, than with treatment with olanzapine alone.
No Mortality Increase With Antipsychotics in Prospective StudyJune 17th 2013
Results of a 10-week prospective study, recently reported at the Annual Meeting of the American Association for Geriatric Psychiatry, offered no conclusive evidence about the mortality risk of elderly patients with Alzheimer disease who were treated with antipsychotics.
Suicide Risk Associated with Low Omega-3 Fatty AcidsOctober 8th 2011
"I'm all over it, because I'm looking for something to help," declared Army Vice-Chief of Staff General Peter W. Chiarelli, quoted in USA Today News September 20, in his response to a study finding an increased risk of suicide in US military personnel with low Omega-3 fatty acid serum levels.
Methylene Blue Studied for Bipolar as FDA Issues WarningOctober 6th 2011
A study presented by Canadian investigators at the 24th Congress of the European College of Neuropsychopharmacology (ECNP) in Paris, September 5 evaluated whether methylene blue can reduce residual symptoms of depression and mania in bipolar disorder.
Are FDA Warnings on Antipsychotics Heeded?April 7th 2010
The impact of FDA alerts and label warnings was examined in 2 recently published studies of antipsychotic drug use. In one study, researchers gauged physician response to the 2005 warning of increased mortality with antipsychotic use in elderly patients with dementia, and in the other study, researchers determined whether recommended safeguards were implemented following the 2003 advisories on adverse metabolic effects of second-generation antipsychotics.
New Recommendations for Treatment of SchizophreniaFebruary 6th 2010
Newly published recommendations for pharmacological and psychosocial treatments from the Schizophrenia Patient Outcomes Research Team (PORT) are the first to address related treatments, such as smoking cessation, substance abuse, and weight loss, and they are the first update since 2003.
Addictions Conference Assesses TreatmentsDecember 30th 2009
The empirical basis for the effectiveness of 12-step recovery and the psychotherapeutic benefits of opioid agonist maintenance were among the topics of several symposia with introspective views of time-tested treatments at the 40th Annual Medical-Scientific Conference of the American Society of Addiction Medicine (ASAM) in New Orleans.
Atypical Antipsychotics Increase Cardiometabolic Risk in ChildrenDecember 29th 2009
A study of the adverse effects of 4 second-generation antipsychotics in children and adolescents documented substantial weight gain during 11 weeks of treatment with each agent, with the increased abdominal fat that has been associated with development of metabolic syndrome in adults. Metabolic abnormalities emerged with 3 of the 4 agents, differing in type and severity with the agent and, in some cases, with the dose.
Focus on Pharmacotherapy Studies in the ElderlyNovember 23rd 2009
The NIMH-sponsored New Clinical Drugs Evaluation Unit (NCDEU) meeting is a favored venue for reports and reviews of NIH-funded psychopharmacological studies, and this was true of the recent annual meeting in Hollywood, Fla. The meeting included a workshop on new investigations of antidepressant use in Alzheimer disease and a panel session on the safety of pharmacotherapy in older adults.
Advocates Call for Treating Tobacco Dependence in Psychiatric PatientsNovember 7th 2009
Smoking cessation services should be integrated into substance use disorder treatment programs, according to David Kalman, MD, Department of Psychiatry, University of Massachusetts, and colleagues, in their recent review of tobacco dependency among patients who sought treatment for alcoholism.1